title: Iloprost in the management of peripheral arterial disease in patients with diabetes mellitus.
abstract: Diabetic complications in the lower extremities, especially those secondary to diabetic macroangiopathy, have increasingly become a clinical emergency, given the high prevalence and progression of the disease. Until recently, the only approach to treating advanced stage disease was medical therapy and major amputation; however, the advent of revascularization procedures has radically improved the prognosis of patients with critical lower limb ischemia. In this setting, iloprost holds a dual position: as first-choice therapy in patients ineligible for revascularization and as complementary therapy in candidates for surgical or endovascular revascularization.
authors.affiliation: Sezione Piede Diabetico, Unità Operativa Malattie del Metabolismo e Diabetologia, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italia. piaggesi@immr.med.unipi.it
authors.forename: A
authors.initials: A
authors.lastname: Piaggesi
authors.forename: V
authors.initials: V
authors.lastname: Vallini
authors.forename: E
authors.initials: E
authors.lastname: Iacopi
authors.forename: A
authors.initials: A
authors.lastname: Tedeschi
authors.forename: A
authors.initials: A
authors.lastname: Scatena
authors.forename: C
authors.initials: C
authors.lastname: Goretti
authors.forename: L
authors.initials: L
authors.lastname: Rizzo
mesh_terms: D003925:Diabetic Angiopathies / Q000188:drug therapy*; D004347:Drug Interactions; D006801:Humans; D016285:Iloprost / Q000627:therapeutic use*; D058729:Peripheral Arterial Disease / Q000188:drug therapy*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D011453:Prostaglandins / Q000627:therapeutic use
chemical_list: D010975:Platelet Aggregation Inhibitors; D011453:Prostaglandins; D016285:Iloprost